The research is published in a special issue of the journal Science focusing on the genome sequences of Trypanosoma brucei, Trypanosoma cruzi, and Leishmania major and the public health threat that these parasites represent. One of the studies' key findings is the identification of gene sequences that are involved in the host-parasite relationship and in the regulation of the parasite metabolism.
Shulamit Michaeli, a HHMI international research scholar at Bar-Ilan University in Israel and co-author on the L. major paper, is optimistic about the impact of the work on drug development. "By providing information on virulence factors, critical enzymes in key metabolic pathways, and potential vaccine candidates, this study will advance tropical medicine by helping us develop new drugs against these diseases," she said.
Alberto Frasch, a HHMI international scholar from Argentina, agrees. "Having a sequenced genome should aid us immeasurably in finding new drugs," said Frasch, who is director of the Institute for Research in Biotechnology of the National University of General San Martin in Buenos Aires and an author on the T. cruzi and L. major papers. Frasch explained that the drugs currently available to treat diseases caused by trypansomes "either have toxic side effects or lack efficiency in some stages of infection, as in chronic Chagas disease." "Also," he said, "drug resistance in diseases caused by trypanosomat
Contact: Jennifer Donovan
Howard Hughes Medical Institute